Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/b4/36/7b/b4367b37-46e0-b7d1-1dd6-e8631c141cf9/mza_10753429545898377801.jpg/600x600bb.jpg
NHS Specialist Pharmacy Service
NHS Specialist Pharmacy Service
87 episodes
5 days ago
Penny Daynes, Associate Regional Pharmacy procurement specialist at SPS, presents a summary of the resources published by SPS between 1st and 7th November.  To easily find a list of newly published pages go to sps.nhs.uk, select ‘search’, click in the search bar, and press enter.     Quick links to highlighted resources:    The licence and supporting evidence for ranibizumab biosimilars Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence https://www.sps.nhs.uk/articles/the-licence-and-supporting-evidence-for-ranibizumab-biosimilar/ Preparing to use ranibizumab biosimilar Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team https://www.sps.nhs.uk/articles/preparing-to-use-ranibizumab-biosimilar/ Restricted to NHS: The licence and supporting evidence for aflibercept biosimilars (log in required) Aflibercept 2mg biosimilars Afqlir, Eydenzelt, Yesafili and Vgenfli are expected in December 2025 for NHS use. Learn about supporting evidence and differences. https://www.sps.nhs.uk/articles/the-licence-and-supporting-evidence-for-aflibercept-biosimilars/ New Medicines News New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes. https://www.sps.nhs.uk/articles/new-medicines-news/ Medicines Governance Do Once (MGDO) programme opportunity Contact jo.jenkins2@nhs.net for more information. Closing date for applications 30 November 2025. Next events Forthcoming webinars and conferences       https://www.sps.nhs.uk/home/events/next-events/      Join our new WhatsApp channel to stay up to date with our latest news and updates https://whatsapp.com/channel/0029VbBslvuJpe8aH3n7Zu1i Podcast description:     NHS Specialist Pharmacy Service serves healthcare professionals across the NHS who are involved in all aspects of buying, making and using medicines. Our motto is 'do once and share'.   
Show more...
Health & Fitness
RSS
All content for NHS Specialist Pharmacy Service is the property of NHS Specialist Pharmacy Service and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Penny Daynes, Associate Regional Pharmacy procurement specialist at SPS, presents a summary of the resources published by SPS between 1st and 7th November.  To easily find a list of newly published pages go to sps.nhs.uk, select ‘search’, click in the search bar, and press enter.     Quick links to highlighted resources:    The licence and supporting evidence for ranibizumab biosimilars Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence https://www.sps.nhs.uk/articles/the-licence-and-supporting-evidence-for-ranibizumab-biosimilar/ Preparing to use ranibizumab biosimilar Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team https://www.sps.nhs.uk/articles/preparing-to-use-ranibizumab-biosimilar/ Restricted to NHS: The licence and supporting evidence for aflibercept biosimilars (log in required) Aflibercept 2mg biosimilars Afqlir, Eydenzelt, Yesafili and Vgenfli are expected in December 2025 for NHS use. Learn about supporting evidence and differences. https://www.sps.nhs.uk/articles/the-licence-and-supporting-evidence-for-aflibercept-biosimilars/ New Medicines News New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes. https://www.sps.nhs.uk/articles/new-medicines-news/ Medicines Governance Do Once (MGDO) programme opportunity Contact jo.jenkins2@nhs.net for more information. Closing date for applications 30 November 2025. Next events Forthcoming webinars and conferences       https://www.sps.nhs.uk/home/events/next-events/      Join our new WhatsApp channel to stay up to date with our latest news and updates https://whatsapp.com/channel/0029VbBslvuJpe8aH3n7Zu1i Podcast description:     NHS Specialist Pharmacy Service serves healthcare professionals across the NHS who are involved in all aspects of buying, making and using medicines. Our motto is 'do once and share'.   
Show more...
Health & Fitness
https://i1.sndcdn.com/artworks-naLsSmtOhdaHrWrG-yMOIGg-t3000x3000.png
Pharmacy First: Infected Insect Bites
NHS Specialist Pharmacy Service
13 minutes 53 seconds
10 months ago
Pharmacy First: Infected Insect Bites
Kieran Reynolds talks to Dr Stephanie Gallard and Liz Kramer about some of the clinical issues you may encounter when providing the infected insect bites/stings service under Pharmacy First. Discussion includes how to differentiate between infected and non-infected insect bites, advice to give patients to prevent insect bites from becoming infected and how patients with insect borne diseases may present. (13m 53) Dr Stephanie Gallard – GP with special interest in dermatology, PCDS Executive committee member Kieran Reynolds – Advanced Specialist Pharmacist (Medicines Governance), SPS Liz Kramer – Community Pharmacist Useful links: NHS Lyme disease https://www.nhs.uk/conditions/lyme-disease/ PCDS Lyme disease https://www.pcds.org.uk/clinical-guidance/lyme-disease Tick Borne Encephalitis https://www.nhs.uk/conditions/tick-borne-encephalitis/ Malaria https://www.nhs.uk/conditions/malaria/
NHS Specialist Pharmacy Service
Penny Daynes, Associate Regional Pharmacy procurement specialist at SPS, presents a summary of the resources published by SPS between 1st and 7th November.  To easily find a list of newly published pages go to sps.nhs.uk, select ‘search’, click in the search bar, and press enter.     Quick links to highlighted resources:    The licence and supporting evidence for ranibizumab biosimilars Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence https://www.sps.nhs.uk/articles/the-licence-and-supporting-evidence-for-ranibizumab-biosimilar/ Preparing to use ranibizumab biosimilar Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team https://www.sps.nhs.uk/articles/preparing-to-use-ranibizumab-biosimilar/ Restricted to NHS: The licence and supporting evidence for aflibercept biosimilars (log in required) Aflibercept 2mg biosimilars Afqlir, Eydenzelt, Yesafili and Vgenfli are expected in December 2025 for NHS use. Learn about supporting evidence and differences. https://www.sps.nhs.uk/articles/the-licence-and-supporting-evidence-for-aflibercept-biosimilars/ New Medicines News New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes. https://www.sps.nhs.uk/articles/new-medicines-news/ Medicines Governance Do Once (MGDO) programme opportunity Contact jo.jenkins2@nhs.net for more information. Closing date for applications 30 November 2025. Next events Forthcoming webinars and conferences       https://www.sps.nhs.uk/home/events/next-events/      Join our new WhatsApp channel to stay up to date with our latest news and updates https://whatsapp.com/channel/0029VbBslvuJpe8aH3n7Zu1i Podcast description:     NHS Specialist Pharmacy Service serves healthcare professionals across the NHS who are involved in all aspects of buying, making and using medicines. Our motto is 'do once and share'.